Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
紐約州塔裏敦，2024年5月6日（環球新聞專線）——Regeneron Pharmicals, Inc.（納斯達克股票代碼：REGN）將通過網絡直播管理層的參與情況如下：
- RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024
- Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024
- Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024
- 加拿大皇家銀行資本市場全球醫療保健會議將於美國東部時間2024年5月14日星期二上午9點舉行
- 傑富瑞全球醫療保健會議將於美國東部時間2024年6月5日星期三上午 8:30 舉行
- 高盛 45第四 年度全球醫療保健會議將於美國東部時間2024年6月11日星期二上午8點舉行
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
可從Regeneron網站的 “投資者與媒體” 頁面訪問這些會議，網址爲 https://investor.regeneron.com/events-and-presentations。網絡廣播的重播和記錄將在公司網站上存檔至少30天。
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
關於 Regeneron
Regeneron（納斯達克股票代碼：REGN）是一家領先的生物技術公司，爲嚴重疾病患者發明、開發和商業化改變生活的藥物。我們由醫師兼科學家創立和領導，具有反覆持續地將科學轉化爲醫學的獨特能力，促成了許多獲得批准的療法和候選產品正在開發中，其中大多數是在我們的實驗室中本土研發的。我們的藥物和產品線旨在幫助患有眼部疾病、過敏和炎性疾病、癌症、心血管和代謝疾病、神經系統疾病、血液系統疾病、傳染病和罕見疾病的患者。
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Regeneron 使用我們的專有技術突破科學發現的界限並加速藥物開發，例如 Veloci 套件，它可產生優化的全人抗體和新類別的雙特異性抗體。我們正在利用再生元遺傳學中心的數據驅動見解塑造下一個醫學前沿 以及開創性的基因醫學平台，使我們能夠確定可能治療或治癒疾病的創新靶標和補充方法。
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
欲了解更多信息，請訪問 www.regeneron.com 或者繼續關注 Regeneron 領英， Instagram， Facebook 要麼 X。
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
聯繫信息：
投資者關係
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Source: Regeneron Pharmaceuticals, Inc.
來源：Regeneron Pharmicals, Inc.